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Surgery is the main curative treatment for early stage NSCLC. Never-
theless, more than 50 % of patients die of tumor progression after com-
plete surgical resection. Recurrence occurs outside the chest in about 
two third of cases and deserves the use of adjuvant treatments.
In the early 90’s, the Medical Research Council and Institut Gustave-
Roussy performed a large overview on the role of chemotherapy in 
NSCLC using updated individual data. A 13% reduction in the risk of 
death was observed, suggesting an absolute beneﬁt of 5% with adjuvant 
chemotherapy at 5 years (p=0.08). Sex, performance status, age and 
histologic subtype had no impact on this effect. These results consti-
tuted the rationale for a new generation of randomized studies with 
platin-based regimens.
A North American Intergroup Trial (Int 0115) demonstrated that a 
combination of 4 cycles of chemotherapy (etoposide-cisplatin) plus 
concomitant thoracic radiotherapy was not superior to radiotherapy 
alone given at the same dose in 463 patients with resected stage II and 
IIIA NSCLC. Additionally, there was no impact of the p53 and k-ras 
modiﬁcations on the outcome of patients. 
In the ALPI trial, patients with resected stage I-IIIa NSCLC were 
randomly allocated to receive either 3 courses of MVP (Mitomycin 8 
mg/m2 day 1; Vindesine 3mg/m2 day 1 and 8; Cisplatin 100 mg/m2 day 
1 every 3 weeks for 3 cycles) or no adjuvant treatment after complete 
resection. Overall 1209 patients were enrolled into the study, 606 in 
the chemotherapy arm and 603 in the control arm. In the chemotherapy 
arm, 69% of patients completed the treatment but half of them had trea-
ment modiﬁcations. Radiotherapy was delivered in 482 patients. A total 
of 1088 patients were analysed with a median follow-up of 63 months. 
H.R. was 0.94 for overall survival and 0.89 for disease-free survival. 
No statistically signiﬁcant difference was observed even if the differ-
ence was borderline signiﬁcant for stage II disease.
The IALT was a large worldwide randomized study whose aim was to 
determine the impact on overall survival of 3 to 4 cycles of a cisplatin-
based chemotherapy (CT) regimen after complete surgical resection in 
patients with stage I-III NSCLC. Thoracic radiotherapy might be given 
according to the preregistration policy of each centre. There were 932 
pts allocated to CT and 67% received at least 300 mg/m2 of cisplatin. 
The drug combined with cisplatin was etoposide (56%), vinorelbine 
(27%), vinblastine (11%) and vindesine (6%). There were 935 pts in 
the control arm. After a median follow-up of 56 months, overall sur-
vival was signiﬁcantly different between the 2 arms: 2 and 5-yr survival 
rates were 70% and 45 % in the CT arm vs 67% and 40% in the control 
arm respectively (RR=0.86 [0.76-0.98], p<0.03). Disease-free survival 
was also signiﬁcantly different: 61 % and 39% in the CT arm vs 55% 
and 34% in the control arm at 2 and 5 yrs respectively (RR=0.83 [0.74-
0.94], p<0.003). No signiﬁcant interaction was observed with age, 
gender, PS, type of surgery, pStage, histology, cisplatin dose, combined 
drug, radiotherapy. ERCC1 was immunohistochemically evaluated 
in 761 tumor specimens of patients. ERCC1 expression was positive 
in 44% and negative in 56%. A beneﬁt from cisplatin-based adjuvant 
chemotherapy was associated with the negative expression of ERCC1 
(test for interaction, p=0.009)
In the post-operative subgroup of the Big Lung Trial, no beneﬁt from 
adjuvant chemotherapy was observed among 381 patients but the popu-
lation was not heterogeneous in particular concerning the quality of the 
resection, and the compliance to chemotherapy was poor.
A Japanese randomized study compared adjuvant UFT for 2 years to no 
treatment in patients with completely resected stage I NSCLC. Among 
979 eligible patients, there was a signiﬁcant advantage in favor of UFT 
(p=0.036) but the beneﬁt was restricted to the 27% of patients with 
T2N0 NSCLC. At the 2004 ASCO meeting, the Japanese adjuvant UFT 
meta-analysis conﬁrmed a signiﬁcant advantage of the drug compared 
to control in 2003 patients (p<0.001).
The NCI-Canada conducted a phase III trial (JBR 10) comparing sur-
gery alone to surgery followed by adjuvant chemotherapy with cisplatin 
and vinorelbine in 459 eligible patients with stage Ib and II resected 
NSCLC. They showed a 15% beneﬁt at 5 years (p=0.012). The beneﬁt 
was restricted to stage II patients.
The CALGB also conducted a randomized trial in 344 patients with 
stage Ib NSCLC (CALGB 9633). The initial beneﬁt at 4 years reported 
with adjuvant Paclitaxel-Carboplatin compared to no adjuvant treat-
ment was not conﬁrmed with a longer follow-up and the beneﬁt is only 
3% at 5 years (p=0.10).
In the ANITA 1 trial, which also concerned patients with completely re-
sected NSCLC, chemotherapy consisted of 4 cycles of cisplatin at 100 
mg/m2 every 4 weeks and 16 cycles of vinorelbine at 30 mg/m2 weekly 
compared to a control arm. A total of 831 patients were included from 
October 1994 to December 2000. There were 35% stage I, 30% stage II 
and 35% stage III. Again, there was a survival advantage for adjuvant 
chemotherapy. Survival rates were 68%, 51%and 45% at 2, 5 and 7 
years in the chemotherapy arm vs 63%, 43% and 37% respectively. RR 
was 0.80 [0.66-0.96] with a p value of 0.017.
The LACE meta-analysis reported at ASCO 2006 included a total of 
4584 patients accrued in the 5 recent cisplatin-based adjuvant trials. It 
conﬁrmed the beneﬁt of adjuvant chemotherapy with a 5.3% improve-
ment of survival at 5 years (p=0.0043). Disease-free survival was also 
improved (5.2% at 5 years, p<0.0001).
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Looking at the pathological stage, there was a negative effect of adju-
vant chemotherapy for stage Ia. The risk reduction was 8% for stage Ib, 
17% for stages II and III.
The effect of chemotherapy did not vary according to age, gender, PS, 
type of surgery and histology.
When the drug combined with cisplatin was analyzed, the risk reduc-
tion was 20% for Vinorelbine, 7% for other biotherapies and 2% for 
tritherapies.
In the 1888 patients who received the combination of vinorelbine and 
cisplatin, the 5-year absolute beneﬁt was 9% and the hazard ratio was 
0.95 (0.76-1.20) for stage I vs 0.68 (0.56-0.83) and 0.62 (0.50-0.76) for 
stage II and III respectively. 
In conclusion, the results of the recently reported large randomized 
studies of adjuvant chemotherapy suggest a 5 to 15% improvement of 
survival at 5 years.The LACE pooled analysis of the new generation of 
trials has included over 4,000 patients. It conﬁrms the role of adjuvant 
chemotherapy in resected NSCLC except for stage Ia patients. It sug-
gests the use of vinorelbine in combination with cisplatin. The results 
of the IALT-Bio program suggest to evaluate the expression of ERCC1 
in order to determine which patients are more likely to beneﬁt from 
chemotherapy. If these results are conﬁrmed, we will enter the era of 
tailored therapy for resected NSCLC. 
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Several prospective randomized trials for patients with early stage 
NSCLC (stages I-IIIA) have conﬁrmed a survival beneﬁt with 
cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 
meta-analysis performed by the NSCLC Collaborative Group. On the 
other hand, uracil-tegafur was also shown to improve survival among 
patients with stage I adenocarcinoma in Japan.
Japan Lung Cancer Research Group trial: Attending physicians 
of this group randomly assigned patients with completely resected 
pathological stage I adenocarcinoma of the lung to receive either oral 
uracil-tegafur (250 mg of tegafur per square meter of body-surface area 
per day) for two years or no treatment. Randomization was performed 
with stratiﬁcation according to the pathological tumor category (T1 
vs. T2), sex, and age. From January 1994 through March 1997, 999 
patients were enrolled. Twenty patients were found to be ineligible and 
were excluded from the analysis after randomization; 491 patients were 
assigned to receive uracil-tegafur and 488 were assigned to observa-
tion. The median duration of follow-up for surviving patients was 73 
months. The difference in overall survival between the two groups was 
statistically signiﬁcant in favor of the uracil-tegafur group (P=0.04 by a 
stratiﬁed log-rank test). Grade 3 toxic effects occurred in 10 of the 482 
patients (2 percent) who actually received uracil-tegafur. This trial has 
demonstrated adjuvant therapy with uracil-tegaful (UFT) afforded an 
improvement of 4% in the 5-year survival rate and a relative risk reduc-
tion of 26% in mortality at 5 years among patients with T1-2N0 (stage 
I) disease. In particular, an improvement in the 5-year survival rate of 
11%, favoring chemotherapy with UFT has been reported in the subset 
of patients with T2N0 (stage IB) disease.
Meta-analysis of six UFT trials: Among nine trials of postoperative 
adjuvant UFT-containing chemotherapy, six trials comparing surgery 
alone with surgery plus UFT were identiﬁed. Of six trials, two were 
three-arm trials including cisplatin-based chemotherapy followed by 
UFT, and data from that arm were not included in the meta-analysis. Of 
2,003 eligible patients, most (98.8%) had squamous cell carcinoma or 
adenocarcinoma, and most had stage I disease; the tumor classiﬁcation 
was T1 in 1,308 (65.3%), T2 in 674 (33.6%), and the nodal status was 
N0 in 1,923 (96.0%). The two treatment groups did not differ signiﬁ-
cantly in major prognostic factors. The median duration of follow-up 
was 6.44 years. The survival rates at 5 and 7 years were signiﬁcantly 
higher in the surgery plus UFT group (81.5% and 76.5%, respectively) 
than in the surgery alone group (77.2% and 69.5%, respectively; P = 
.011 and .001, respectively). The overall pooled hazard ratio was 0.74, 
and its 95% CI was 0.61 to 0.88 (P = .001). This meta-analysis showed 
that postoperative adjuvant chemotherapy with UFT was associated 
with improved 5- and 7-year survival in a Japanese patient population 
composed primarily of stage I adenocarcinoma patients. Another meta-
analyses based on abstracts have estimated a relative risk reduction in 
mortality of 11-13% at 5 years.
